The success rate of "test-tube babies" is gradually increasing around the world, with an average of about 30~40%. Some centers report success rates< font color="#FF0066">50%. This is in line with the laws of nature, because the pregnancy rate of young married women in one month of normal sexual intercourse does not exceed 30%. Due to the high cost of this treatment and the high price of imported drugs, each cycle costs approximately 8,000 to 10,000 yuan, as well as the remaining surgical fees and laboratory materials. The consumption and operating expenses will cost about6000~10000 yuan, and it is difficult to continue to improve the success rate. The patient decided to undergo this treatment. You should be financially prepared, fully understand the outcome of treatment, and cooperate with medical staff.

The possibility of miscarriage or intrauterine fetal arrest is higher with “test-tube babies” than with natural pregnancy. If confirmed, termination of pregnancy should be considered promptly to avoid massive bleeding and infection. Because multiple embryos are transplanted each time, the incidence of multiple births is also high. Multiple pregnancy is prone to complications and premature birth. In principle, if there are more than triplets, fetal reduction surgery should be performed. However, fetal reduction surgery has a 10% chance of causing the abortion of all embryos.

If the patient’s fallopian tubes are not completely blocked, the embryos transplanted into the uterine cavity may flow into the fallopian tubes and cause ectopic pregnancy. Sometimes, intrauterine and ectopic pregnancy may even occur. High attention should be paid to early diagnosis and treatment to avoid risks such as heavy bleeding.

Any fetal malformation that occurs in natural pregnancy can occur in "test-tube babies", but the malformation rate is not higher than that in natural pregnancy.

This article comes from adult.6kmall.com and is published by netizens. This site only quotes it for reference. It does not mean that this site agrees with the views of the article. If you believe that the content and intellectual property rights of this article infringe upon your interests, please contact us.